2,637
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of Exacerbation and Symptom-Free Time in Patients with COPD

, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 9-17 | Received 06 Jun 2022, Accepted 08 Oct 2022, Published online: 11 Jan 2023
 

Abstract

In clinical practice, clinicians mainly focus on Chronic Obstructive Pulmonary Disease (COPD) exacerbations and symptoms, while patients may prefer to evaluate periods free of COPD exacerbations and deteriorated symptoms. The latter would suit the positive health approach that centralizes people and their beliefs. We aimed to identify patient characteristics and health outcomes relating to: 1) COPD exacerbation-free days; 2) days with no more symptoms than usual; and 3) combined COPD exacerbation and comorbid flare-up-free days (i.e. chronic heart failure, anxiety, depression flare-ups) using negative binomial regression analyzes. Data were obtained from two self-management intervention trials including COPD patients with and without comorbidities. 313 patients (mean age 66.0 years, 63.6% male, 68.7% comorbidity) were included. Better baseline chronic respiratory questionnaire (CRQ) fatigue (incidence rate ratio (IRR) = 1.03 (95% CI 1.01–1.05), p = 0.02) and mastery scores (IRR = 1.03 (95% CI 1.00–1.06), p = 0.04) and fewer courses of antibiotics (IRR = 0.95 (95% CI 0.94–0.96), p < 0.01) were related to more COPD exacerbation-free days. Additionally, better baseline CRQ fatigue (IRR = 1.05 (95% CI 1.00–1.10), p = 0.04) and mastery scores (IRR = 1.06 (95% CI 1.00–1.12), p = 0.04), fewer courses of antibiotics (IRR = 0.94 (95% CI 0.91–0.96), p < 0.01), and improved CRQ dyspnea scores over 12 months of follow-up (IRR = 1.07 (95% CI 1.01–1.12), p < 0.01) were correlated to more days free of deteriorated symptoms. Less baseline dyspnea (modified Medical Research Council score) (IRR = 0.95 (95% CI 0.92–0.98), p < 0.01) and fewer courses of antibiotics (IRR = 0.94 (95% CI 0.93–0.95), p < 0.01) were associated with more combined COPD exacerbation and comorbid flare-up-free days. Healthcare professionals should be aware that less fatigue and better mastering of COPD relate to more exacerbation and symptom-free time in COPD patients.

Data availability statement

Data that support the findings of this study are available upon reasonable request (corresponding author, A. Lenferink).

Declaration of interest

The COPE-II study was financially supported by the Lung Foundation Netherlands (grant number 3.4.02.12). The COPE-III study was financially supported by the Lung Foundation Netherlands (grant number 3.4.11.061), Lung Foundation Australia (Australian Lung Foundation Boehringer Ingelheim COPD Research Fellowship 2010), Repat Foundation, GlaxoSmithKline (unrestricted grant) and Stichting Astma Bestrijding.

Additional information

Funding

The COPE-II study was financially supported by the Lung Foundation Netherlands (grant number 3.4.02.12). The COPE-III study was financially supported by the Lung Foundation Netherlands (grant number 3.4.11.061), Lung Foundation Australia (Australian Lung Foundation Boehringer Ingelheim COPD Research Fellowship 2010), Repat Foundation, GlaxoSmithKline (unrestricted grant) and Stichting Astma Bestrijding.